PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1529986
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1529986
Global medical affairs outsourcing market is estimated to be valued at USD 2.31 Bn in 2024 and is expected to reach USD 5.21 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.3% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | US$ 2.31 Bn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
Forecast Period 2024 to 2031 CAGR: | 12.30% | 2031 Value Projection: | US$ 5.21 Bn |
Rising drug development costs and complex regulatory requirements have compelled pharmaceutical and biotech companies to increasingly rely on external expertise and services. Medical affairs outsourcing helps to reduce development expenses and speeds up clinical trials and new product launches. It allows companies to stay focused on core competencies while benefitting from specialized skills and insights of outsourcing partners. Various services offered include medical information, medical monitoring, medical reporting and publication planning, along with regulatory support. Advancements in technology have enabled remote and flexible working models, thus, boosting the scope of outsourced activities. Continued digitalization and growing R&D investment in drug development can drive the medical affairs outsourcing market growth.
Global medical affairs outsourcing market growth is driven by factors like rising drug development costs, stringent regulatory norms, and focus on core competencies by pharmaceutical firms. The average cost of developing a new drug has increased substantially over the past few decades to over US$ 2.6 billion currently. Outsourcing certain functions helps to lower costs substantially. Regulatory requirements have also become more complex globally with greater paperwork and compliance standards. Medical affairs outsourcing allows companies to leverage specialized expertise to navigate regulations efficiently. It also allows companies to focus more on core drug discovery and marketing activities while non-core functions are outsourced. Data security and loss of control over critical processes can hamper the market growth. Technological advancements like artificial intelligence and blockchain offers opportunities by enabling remote services and greater data management capabilities.
Detailed Segmentation-